Sourin Bhuniya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sourin Bhuniya has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Prasanta Raghab Mohapatra
Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha
6 shared publications - Manoj Kumar Panigrahi
Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha
4 shared publications Prasanta Raghab Mohapatra
All India Institute of Medical Sciences (AIIMS) Bhubaneswar, Bhubaneswar (Odisha), India
3 shared publicationsGopal Durgeshwar
All India Institute of Medical Sciences (AIIMS) Jodhpur, Jodhpur (Rajasthan), India
2 shared publications- Mahismita Patro
Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha
2 shared publications Manoj Kumar Panigrahi
Department of Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences, Bhubaneswar
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
Association of the six-minute walk test with severity of obstructive sleep apnea: an observational study
Obstructive sleep apnea (OSA) impairs sleep quality and exercise capacity through intermittent hypoxia and autonomic dysfunction. Simple tools that correlate objective exercise tolerance with OSA severity remain underutilized in clinical practice. The study aimed to find the association between 6-minute walk test (6MWT) performance and polysomnographic severity indices in patients with newly diagnosed OSA and whether functional exercise parameters can predict OSA severity. This cross-sectional observational study was conducted at a tertiary care center between July 2023 and January 2025. A total of 124 consecutive adults (age ≥18 years) with newly diagnosed OSA diagnosed from level I polysomnography (PSG) underwent standardized 6MWT as per American Thoracic Society Guidelines within one week of PSG testing. Primary endpoints included 6-minute walk distance (6MWD), oxygen saturation changes, post-test Borg dyspnea scale, and heart rate recovery at 1, 2, and 3 minutes. Correlations with Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) were analyzed using Spearman’s correlation, multiple linear regression, and one-way analysis of variance with Games-Howell post-hoc testing. The study included 124 participants (85.5% male, mean age 46±11.3 years, mean body mass index 33.19±5.9 kg/m²), of whom 79.8% were participants with severe OSA. Mean AHI and ODI were 52.25±23.69 and 54.04±29.22 events/hour, respectively. Mean 6MWD decreased significantly across OSA severity groups: mild 420.85±17.4 m, moderate 396.99±9.60 m, and severe 348.61±22.01 m. Strong negative correlations were found between AHI and 6MWD (ρ=-0.974, p<0.001) and ODI and 6MWD (ρ=-0.775, p<0.001). Multiple linear regression results in two important predictive models: AHI=258.65+[(0.58×Epworth Sleepiness Scale (ESS)] + (1.89×Borg dyspnea post-6MWT) - (0.1×6MWD) and ODI=207.88+(0.96×ESS) + (4.21×Borg dyspnea post-6MWT) - (0.51×6MWD). As measured by the 6MWT, functional exercise capacity is strongly and inversely associated with the severity of OSA. The derived regression equations serve as a valuable, practical adjunct for assessing the functional impairment and hypoxic burden in patients with OSA, particularly in resource-limited settings.
- 29 October 2026
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
Open AccessAssociation of the six-minute walk test with severity of obstructive sleep apnea: an observational study
Obstructive sleep apnea (OSA) impairs sleep quality and exercise capacity through intermittent hypoxia and autonomic dysfunction. Simple tools that correlate objective exercise tolerance with OSA severity remain underutilized in clinical practice. The study aimed to find the association between 6-minute walk test (6MWT) performance and polysomnographic severity indices in patients with newly diagnosed OSA and whether functional exercise parameters can predict OSA severity. This cross-sectional observational study was conducted at a tertiary care center between July 2023 and January 2025. A total of 124 consecutive adults (age ≥18 years) with newly diagnosed OSA diagnosed from level I polysomnography (PSG) underwent standardized 6MWT as per American Thoracic Society Guidelines within one week of PSG testing. Primary endpoints included 6-minute walk distance (6MWD), oxygen saturation changes, post-test Borg dyspnea scale, and heart rate recovery at 1, 2, and 3 minutes. Correlations with Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) were analyzed using Spearman’s correlation, multiple linear regression, and one-way analysis of variance with Games-Howell post-hoc testing. The study included 124 participants (85.5% male, mean age 46±11.3 years, mean body mass index 33.19±5.9 kg/m²), of whom 79.8% were participants with severe OSA. Mean AHI and ODI were 52.25±23.69 and 54.04±29.22 events/hour, respectively. Mean 6MWD decreased significantly across OSA severity groups: mild 420.85±17.4 m, moderate 396.99±9.60 m, and severe 348.61±22.01 m. Strong negative correlations were found between AHI and 6MWD (ρ=-0.974, p<0.001) and ODI and 6MWD (ρ=-0.775, p<0.001). Multiple linear regression results in two important predictive models: AHI=258.65+[(0.58×Epworth Sleepiness Scale (ESS)] + (1.89×Borg dyspnea post-6MWT) - (0.1×6MWD) and ODI=207.88+(0.96×ESS) + (4.21×Borg dyspnea post-6MWT) - (0.51×6MWD). As measured by the 6MWT, functional exercise capacity is strongly and inversely associated with the severity of OSA. The derived regression equations serve as a valuable, practical adjunct for assessing the functional impairment and hypoxic burden in patients with OSA, particularly in resource-limited settings.
- Open Access
- 24 July 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (8) , 206
Evaluating the Gaps in the Diagnosis and Treatment in Extra-Pulmonary Tuberculosis Patients Under National Tuberculosis Elimination Programme (NTEP) Guidelines: A Multicentric Cohort Study
Extra-pulmonary tuberculosis (EPTB) can affect any organ of the body, producing a wide variety of clinical manifestations that make the diagnosis and treatment of EPTB challenging. The optimum treatment varies depending on the site of EPTB, its severity, and response to treatment. There is often uncertainty about the best management practices, with a significant departure from national guidelines. This study aims to identify gaps and barriers in adhering to the national guidelines for the diagnosis and treatment of EPTB. We included 433 patients having EPTB and followed up at predefined intervals of 2 months, 6 months, 9 months, and 12 months. Questionnaire-based interviews of the treating physician and the patients in different departments were conducted. For confirmatory diagnosis, heavy dependence on clinical-radiological diagnosis without microbiological support was observed, which is a deviation from National Tuberculosis Elimination Programme (NTEP) guidelines and raises concerns about the potential for misdiagnosis and overtreatment. Apart from patient delays, long health system delays in EPTB were observed. The median patient delay, health system delay, and total treatment delay times were 4.2, 4, and 10.1 weeks, respectively. To enhance EPTB diagnosis and management, there is a pressing need for improved access to microbiological testing, enhanced physician training on adherence to NTEP guidelines, and greater utilisation of imaging and histopathological techniques.
- 24 July 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (8) , 206
Open AccessEvaluating the Gaps in the Diagnosis and Treatment in Extra-Pulmonary Tuberculosis Patients Under National Tuberculosis Elimination Programme (NTEP) Guidelines: A Multicentric Cohort Study
Extra-pulmonary tuberculosis (EPTB) can affect any organ of the body, producing a wide variety of clinical manifestations that make the diagnosis and treatment of EPTB challenging. The optimum treatment varies depending on the site of EPTB, its severity, and response to treatment. There is often uncertainty about the best management practices, with a significant departure from national guidelines. This study aims to identify gaps and barriers in adhering to the national guidelines for the diagnosis and treatment of EPTB. We included 433 patients having EPTB and followed up at predefined intervals of 2 months, 6 months, 9 months, and 12 months. Questionnaire-based interviews of the treating physician and the patients in different departments were conducted. For confirmatory diagnosis, heavy dependence on clinical-radiological diagnosis without microbiological support was observed, which is a deviation from National Tuberculosis Elimination Programme (NTEP) guidelines and raises concerns about the potential for misdiagnosis and overtreatment. Apart from patient delays, long health system delays in EPTB were observed. The median patient delay, health system delay, and total treatment delay times were 4.2, 4, and 10.1 weeks, respectively. To enhance EPTB diagnosis and management, there is a pressing need for improved access to microbiological testing, enhanced physician training on adherence to NTEP guidelines, and greater utilisation of imaging and histopathological techniques.
- 27 June 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 56, 100907
Candida glabrata associated primary pleuro-pulmonary infections: A report of two cases
- 27 June 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 56, 100907
Candida glabrata associated primary pleuro-pulmonary infections: A report of two cases
- 20 April 2023
- Published by European Respiratory Society (ERS)
- Vol. 9 (suppl 11)
Morning testosterone levels in adult males with obstructive sleep apnoea: a cross-sectional study
Background: Obstructive sleep apnoea (OSA) may cause low testosterone levels in men by disrupting the hypothalamic-pituitary-gonadal axis. Obesity, ageing and chronic disease state may also alter testosterone levels Aims and objectives: To compare morning testosterone levels in patients with OSA and those without OSA and to assess the association between morning testosterone levels and apnoea-hypopnea index (AHI), nocturnal hypoxia and obesity Methods: This was a single-centre, cross sectional observational study. Suspected cases of OSA 18-50 years having Epworth sleepiness scale (ESS) >11 or STOP BANG score >3 underwent polysomnography. Healthy male volunteers 18-50 years, without clinical features of OSA along with negative screening questionnaires were recruited as controls. Venous blood samples from both groups were collected between 07.30 and 08.30 AM for testosterone and other biochemical tests. Results: Forty-five cases and 46 controls were analyzed. The mean (±SD) morning serum testosterone levels in OSA and controls were 166.83±9.84 and 221.23 ±14.9 ng/dl respectively (p=0.002). Mean testosterone levels in cases and controls with BMI ≥25kg/m2 were 159.82±60.65 and 238.65±132.63 (p=0.009) and with dyslipidemia were 159.654 ± 56.919 and 242.974 ± 128.272 ng/dl respectively (p=0.007). Significant negative correlation of testosterone level with BMI was found in cases but not in controls (correlation coefficient: -0.33745 vs 0.029868). No significant correlation was found in testosterone level with AHI, ODI and nadir SpO2 Conclusions: Mean serum testosterone levels were low in OSA patients. Obesity and dyslipidemia were associated with significantly low mean testosterone levels in them
- 20 April 2023
- Published by European Respiratory Society (ERS)
- Vol. 9 (suppl 11)
Morning testosterone levels in adult males with obstructive sleep apnoea: a cross-sectional study
Background: Obstructive sleep apnoea (OSA) may cause low testosterone levels in men by disrupting the hypothalamic-pituitary-gonadal axis. Obesity, ageing and chronic disease state may also alter testosterone levels Aims and objectives: To compare morning testosterone levels in patients with OSA and those without OSA and to assess the association between morning testosterone levels and apnoea-hypopnea index (AHI), nocturnal hypoxia and obesity Methods: This was a single-centre, cross sectional observational study. Suspected cases of OSA 18-50 years having Epworth sleepiness scale (ESS) >11 or STOP BANG score >3 underwent polysomnography. Healthy male volunteers 18-50 years, without clinical features of OSA along with negative screening questionnaires were recruited as controls. Venous blood samples from both groups were collected between 07.30 and 08.30 AM for testosterone and other biochemical tests. Results: Forty-five cases and 46 controls were analyzed. The mean (±SD) morning serum testosterone levels in OSA and controls were 166.83±9.84 and 221.23 ±14.9 ng/dl respectively (p=0.002). Mean testosterone levels in cases and controls with BMI ≥25kg/m2 were 159.82±60.65 and 238.65±132.63 (p=0.009) and with dyslipidemia were 159.654 ± 56.919 and 242.974 ± 128.272 ng/dl respectively (p=0.007). Significant negative correlation of testosterone level with BMI was found in cases but not in controls (correlation coefficient: -0.33745 vs 0.029868). No significant correlation was found in testosterone level with AHI, ODI and nadir SpO2 Conclusions: Mean serum testosterone levels were low in OSA patients. Obesity and dyslipidemia were associated with significantly low mean testosterone levels in them
- 10 April 2023
- Published by Taylor & Francis
- p. 75-80
Diagnostic Interventional Procedures in Melioidosis
The clinical presentation of melioidosis often resembles that of tuberculosis and malignancy. This, coupled with the lack of awareness among physicians about the disease, usually leads to delayed diagnosis and fatal outcomes. The involvement of multiple thoracic and extra-thoracic sites with foci of infection in inaccessible areas makes the diagnosis more difficult. This chapter discusses the various modalities of interventional procedures to obtain clinical specimens from such difficult-to-reach areas to establish the diagnosis of melioidosis. Bronchoscopy-guided procedures such as bronchoalveolar lavage and transbronchial biopsy from lung lesions provide a high yield of definitive diagnosis because there is minimal contamination. Endobronchial ultrasound-guided fine-needle aspiration from mediastinal lymph nodes or lesions and peripheral extraluminal lung lesions helps distinguish melioidosis from other common mimicking diseases. Computed tomography or ultrasound-guided fine-needle aspiration from the various foci of infection followed by microbiological tests clinch the diagnosis in most cases. A high index of suspicion and prompt referral to higher centres having appropriate diagnostic facilities are the keys to early diagnosis of melioidosis.
- 10 April 2023
- Published by Taylor & Francis
- p. 75-80
Diagnostic Interventional Procedures in Melioidosis
The clinical presentation of melioidosis often resembles that of tuberculosis and malignancy. This, coupled with the lack of awareness among physicians about the disease, usually leads to delayed diagnosis and fatal outcomes. The involvement of multiple thoracic and extra-thoracic sites with foci of infection in inaccessible areas makes the diagnosis more difficult. This chapter discusses the various modalities of interventional procedures to obtain clinical specimens from such difficult-to-reach areas to establish the diagnosis of melioidosis. Bronchoscopy-guided procedures such as bronchoalveolar lavage and transbronchial biopsy from lung lesions provide a high yield of definitive diagnosis because there is minimal contamination. Endobronchial ultrasound-guided fine-needle aspiration from mediastinal lymph nodes or lesions and peripheral extraluminal lung lesions helps distinguish melioidosis from other common mimicking diseases. Computed tomography or ultrasound-guided fine-needle aspiration from the various foci of infection followed by microbiological tests clinch the diagnosis in most cases. A high index of suspicion and prompt referral to higher centres having appropriate diagnostic facilities are the keys to early diagnosis of melioidosis.
- 10 January 2023
- Published by Wiley in Respirology
- Vol. 28 (5) , 484-490
Dextromethorphan premedication in the alleviation of cough during flexible bronchoscopy in adults: A randomized double‐blind placebo‐controlled trial
Background and Objective: Cough is invariably encountered during flexible bronchoscopy despite sedation and topical anaesthetics. The ideal cough suppressant during flexible bronchoscopy is not known. We assessed the role of dextromethorphan premedication in relieving the cough during flexible bronchoscopy in adults.Methods: In this single‐centre study, we randomized patients aged ≥18 years to receive dextromethorphan syrup 30 ml (90 mg) or an equal volume of placebo 1 h before the procedure. Patients rated their cough severity and discomfort on a visual analogue scale at the end of the procedure. Bronchoscopists also rated cough severity at the end of the procedure.Results: Out of 112 patients screened, 94 patients (median (interquartile range [IQR]) age 51 (36.25–60.75) years, male: female 2.13:1) were randomized to either the dextromethorphan (n = 47) or placebo (n = 47) groups. The patients‐rated median (IQR) cough scores at the end of the procedure were 15 (10–23) mm in dextromethorphan versus 20 (12–45.5) mm in placebo groups (p = 0.03). Patients‐rated median cough scores at 1 h (5 mm vs. 6 mm, p = 0.21), discomfort scores (12.5 mm vs. 12.5 mm, p = 0.49), and midazolam and lignocaine usage were similar between the two groups. The bronchoscopist‐rated median cough score was non‐significantly lower in the intervention compared to the placebo (26 mm vs. 35 mm, p = 0.09) groups.Conclusion: Dextromethorphan premedication 1 h before flexible bronchoscopy may have an additive effect on cough suppression under conscious sedation and topical lignocaine. Further trials are needed to reiterate our findings with certainty.
- 10 January 2023
- Published by Wiley in Respirology
- Vol. 28 (5) , 484-490
Dextromethorphan premedication in the alleviation of cough during flexible bronchoscopy in adults: A randomized double‐blind placebo‐controlled trial
Background and Objective: Cough is invariably encountered during flexible bronchoscopy despite sedation and topical anaesthetics. The ideal cough suppressant during flexible bronchoscopy is not known. We assessed the role of dextromethorphan premedication in relieving the cough during flexible bronchoscopy in adults.Methods: In this single‐centre study, we randomized patients aged ≥18 years to receive dextromethorphan syrup 30 ml (90 mg) or an equal volume of placebo 1 h before the procedure. Patients rated their cough severity and discomfort on a visual analogue scale at the end of the procedure. Bronchoscopists also rated cough severity at the end of the procedure.Results: Out of 112 patients screened, 94 patients (median (interquartile range [IQR]) age 51 (36.25–60.75) years, male: female 2.13:1) were randomized to either the dextromethorphan (n = 47) or placebo (n = 47) groups. The patients‐rated median (IQR) cough scores at the end of the procedure were 15 (10–23) mm in dextromethorphan versus 20 (12–45.5) mm in placebo groups (p = 0.03). Patients‐rated median cough scores at 1 h (5 mm vs. 6 mm, p = 0.21), discomfort scores (12.5 mm vs. 12.5 mm, p = 0.49), and midazolam and lignocaine usage were similar between the two groups. The bronchoscopist‐rated median cough score was non‐significantly lower in the intervention compared to the placebo (26 mm vs. 35 mm, p = 0.09) groups.Conclusion: Dextromethorphan premedication 1 h before flexible bronchoscopy may have an additive effect on cough suppression under conscious sedation and topical lignocaine. Further trials are needed to reiterate our findings with certainty.
- Open Access
Vaccination saves lives: How do patients with chronic diseases and severe COVID-19 fare? Analysis from India’s National Clinical registry for COVID-19
Objectives: This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalised COVID-19 adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC). Methods: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1 st September 2020 to 26 th October 2021 were examined. Results: Analysis of 29,509 hospitalised, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18752 (63.6%)] showed that 15678 (53.1%) had at least one comorbidity. Among 25715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n=3957). Adjusted odds of dying were significantly higher in age-group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy, and tuberculosis, presenting with dyspnea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6, 7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4, 0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3, 0.7)] were protected from in-hospital mortality. Conclusions: WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality.
Open AccessVaccination saves lives: How do patients with chronic diseases and severe COVID-19 fare? Analysis from India’s National Clinical registry for COVID-19
Objectives: This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalised COVID-19 adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC). Methods: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1 st September 2020 to 26 th October 2021 were examined. Results: Analysis of 29,509 hospitalised, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18752 (63.6%)] showed that 15678 (53.1%) had at least one comorbidity. Among 25715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n=3957). Adjusted odds of dying were significantly higher in age-group ≥60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy, and tuberculosis, presenting with dyspnea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6, 7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4, 0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3, 0.7)] were protected from in-hospital mortality. Conclusions: WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality.
- Open Access
- 4 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e23809
Comparison of Diagnostic Yield and Complications in Ultrasound-Guided Closed Pleural Biopsy Versus Thoracoscopic Pleural Biopsy in Undiagnosed Exudative Pleural Effusion
Malignancy, tuberculosis, and non-tubercular pleural infections account for most exudative pleural effusion. Pleural fluid cytology, biochemical tests and even pleural fluid cell block studies may fail to yield a diagnosis in certain cases. Medical thoracoscopy is the gold standard for the diagnosis of unexplained pleural effusions. However, access to medical thoracoscopy may be limited, particularly in developing countries. Also, certain patients may not be fit to undergo the procedure because of medical conditions. An ultrasound-guided pleural biopsy is an option in such conditions. The present study is intended to compare the diagnostic yield and complications of both methods of pleural biopsy in undiagnosed exudative pleural effusion under a randomized controlled trial. After fulfilling all the inclusion criteria, participants were randomized to either ultrasound-guided closed pleural biopsy or thoracoscopic-guided pleural biopsy groups. The primary outcome was to compare the diagnostic yield of ultrasound-guided Tru-Cut® (Newtech Medical Devices, Faridabad, India) closed pleural biopsy versus thoracoscopic pleural biopsy, and the secondary outcomes were to compare the complications rate, duration of the procedure, and hospital stay in the patients undergoing ultrasound-guided pleural biopsy versus thoracoscopic pleural biopsy, and predictors of a positive biopsy result in both groups. A total of 118 patients with pleural effusion were screened; 39 of them who were eligible, randomized into the ultrasound group (20 patients) and the thoracoscopic group (19 patients). The median age of participants was 53.5 (50-58) years and 55 (45-64) years in the ultrasound and thoracoscopic groups, respectively. Pleural fluid cell count, protein, adenosine deaminase (ADA), and lactate dehydrogenase (LDH) were similar in both groups, although pleural fluid glucose was low in the ultrasound group. Diagnostic yield was 90% (18/20) and 94.7% (18/19) in the ultrasound and thoracoscopic groups, respectively, which was statistically non-significant (p=0.963). The median duration of hospital stay was 9.5 (5.3-27) days and 15 (12-22) days in ultrasound and thoracoscopic groups respectively. The thoracoscopic group had a more prolonged stay compared to the ultrasound group, but it was statistically non-significant (p=0.09). The duration of the procedure was significantly longer in the thoracoscopic group 90 (85-105) minutes, in comparison to ultrasound 47.5 (41.3-55) minutes (p=0.001). No major complications were seen in both groups. Subcutaneous emphysema was the most common complication in the thoracoscopic group (10%), followed by hemorrhage (5.3%), and respiratory failure (5.3%). Hypotension was the only complication in the ultrasound group (5%). The rate of complications was significantly higher in the thoracoscopic group (p<0.01). Ultrasound-guided closed pleural biopsy is as good as thoracoscopic pleural biopsy in undiagnosed exudative pleural effusion. It was associated with a shorter procedure duration, a shorter hospital stay, and fewer complications as compared to thoracoscopic biopsy. Both the procedures were safe in experienced hands and a hospital setup, but the thoracoscopic pleural biopsy was associated with complications.
- 4 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e23809
Open AccessComparison of Diagnostic Yield and Complications in Ultrasound-Guided Closed Pleural Biopsy Versus Thoracoscopic Pleural Biopsy in Undiagnosed Exudative Pleural Effusion
Malignancy, tuberculosis, and non-tubercular pleural infections account for most exudative pleural effusion. Pleural fluid cytology, biochemical tests and even pleural fluid cell block studies may fail to yield a diagnosis in certain cases. Medical thoracoscopy is the gold standard for the diagnosis of unexplained pleural effusions. However, access to medical thoracoscopy may be limited, particularly in developing countries. Also, certain patients may not be fit to undergo the procedure because of medical conditions. An ultrasound-guided pleural biopsy is an option in such conditions. The present study is intended to compare the diagnostic yield and complications of both methods of pleural biopsy in undiagnosed exudative pleural effusion under a randomized controlled trial. After fulfilling all the inclusion criteria, participants were randomized to either ultrasound-guided closed pleural biopsy or thoracoscopic-guided pleural biopsy groups. The primary outcome was to compare the diagnostic yield of ultrasound-guided Tru-Cut® (Newtech Medical Devices, Faridabad, India) closed pleural biopsy versus thoracoscopic pleural biopsy, and the secondary outcomes were to compare the complications rate, duration of the procedure, and hospital stay in the patients undergoing ultrasound-guided pleural biopsy versus thoracoscopic pleural biopsy, and predictors of a positive biopsy result in both groups. A total of 118 patients with pleural effusion were screened; 39 of them who were eligible, randomized into the ultrasound group (20 patients) and the thoracoscopic group (19 patients). The median age of participants was 53.5 (50-58) years and 55 (45-64) years in the ultrasound and thoracoscopic groups, respectively. Pleural fluid cell count, protein, adenosine deaminase (ADA), and lactate dehydrogenase (LDH) were similar in both groups, although pleural fluid glucose was low in the ultrasound group. Diagnostic yield was 90% (18/20) and 94.7% (18/19) in the ultrasound and thoracoscopic groups, respectively, which was statistically non-significant (p=0.963). The median duration of hospital stay was 9.5 (5.3-27) days and 15 (12-22) days in ultrasound and thoracoscopic groups respectively. The thoracoscopic group had a more prolonged stay compared to the ultrasound group, but it was statistically non-significant (p=0.09). The duration of the procedure was significantly longer in the thoracoscopic group 90 (85-105) minutes, in comparison to ultrasound 47.5 (41.3-55) minutes (p=0.001). No major complications were seen in both groups. Subcutaneous emphysema was the most common complication in the thoracoscopic group (10%), followed by hemorrhage (5.3%), and respiratory failure (5.3%). Hypotension was the only complication in the ultrasound group (5%). The rate of complications was significantly higher in the thoracoscopic group (p<0.01). Ultrasound-guided closed pleural biopsy is as good as thoracoscopic pleural biopsy in undiagnosed exudative pleural effusion. It was associated with a shorter procedure duration, a shorter hospital stay, and fewer complications as compared to thoracoscopic biopsy. Both the procedures were safe in experienced hands and a hospital setup, but the thoracoscopic pleural biopsy was associated with complications.
- Open Access
- 1 January 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 32, 101375
Pleural empyema due to Enterococcus species: An uncommon etiology
- 1 January 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 32, 101375
Open AccessPleural empyema due to Enterococcus species: An uncommon etiology
- Open Access
- 10 July 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (3) , 420-424
Utility of endobronchial ultrasound guided trans-bronchial needle aspiration in diagnosis of melioidosis - case series and review of literature
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is routinely performed for diagnostic evaluation of mediastinal lymphadenopathy due to various etiologies with excellent sensitivity and specificity. Melioidosis can have atypical features like isolated mediastinal lymphadenopathy mimicking as tuberculosis or lymphoma. Differentiation of such atypical melioidosis presentation become difficult due to similar clinical, radiological and even similar EBUS lymph node characteristics. Role of EBUS TBNA in diagnosing melioidosis is under investigated and sparsely reported. We describe two cases of melioidosis diagnosed by point of care rapid lateral flow immunoassay antigen testing and culture of EBUS-TBNA samples from necrotic mediastinal lymph nodes.
- 10 July 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (3) , 420-424
Open AccessUtility of endobronchial ultrasound guided trans-bronchial needle aspiration in diagnosis of melioidosis - case series and review of literature
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is routinely performed for diagnostic evaluation of mediastinal lymphadenopathy due to various etiologies with excellent sensitivity and specificity. Melioidosis can have atypical features like isolated mediastinal lymphadenopathy mimicking as tuberculosis or lymphoma. Differentiation of such atypical melioidosis presentation become difficult due to similar clinical, radiological and even similar EBUS lymph node characteristics. Role of EBUS TBNA in diagnosing melioidosis is under investigated and sparsely reported. We describe two cases of melioidosis diagnosed by point of care rapid lateral flow immunoassay antigen testing and culture of EBUS-TBNA samples from necrotic mediastinal lymph nodes.